Navigation Links
Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation
Date:3/8/2010

MEDFORD, Mass., March 8 /PRNewswire/ -- Biocell Center Corporation and Caritas Christi Health Care, New England's largest community-based hospital network, and its flagship hospital St. Elizabeth's Medical Center, are pleased to announce the launch of a cryopreservation service for amniotic fluid stem cells obtained during a routine second trimester amniocentesis procedure.

According to Dr. Lucy Bayer-Zwirello, Chief of Maternal Fetal Medicine at Caritas Christi and Associate Professor of Obstetrics and Gynecology at Tufts University School of Medicine, "Amniotic fluid is one of the richest sources of mesenchymal stem cells that are viewed by many as the next frontier in stem cell therapy, with dozens of studies in cellular therapies and tissue regeneration on-going."    

"We are proud of this very important collaboration," said Dr. Kate Torchilin, CEO of Biocell Center Corporation. "We are looking forward to working with such a prominent New England hospital group as Caritas Christi to bring to its patients the opportunity to cryopreserve the cells from amniotic fluid as a biological insurance for their children."  

"These cells are very young in their development and can become many different cells and tissue types, unlike more developed adult stem cells," Dr. Torchilin added. "Once properly cryopreserved, the amniotic fluid cells can be stored for decades, and from the small sample enough cells can be generated for a potential medical procedure for the child from birth well into adulthood, as well as for immediate family members if required."

Biocell Center has recently been featured in L'Osservatore Romano, the official newspaper of the Vatican, in an interview heralding amniotic fluid stem cells as "the future of medicine" and touting this source of stem cells as morally acceptable. Amniotic fluid stem cells can be easily harvested during amniocentesis, thus making them very easy for the doctor to collect.  

"We see this service as very valuable for our patients because it gives them a unique opportunity to preserve cells for their baby's future. And, as a doctor, I appreciate the ability to give that extra service and option to my patients without any changes to the standard clinical practice," said Dr. Bayer-Zwirello.  

Caritas Christi will be offering this service as part of the standard genetic amniocentesis procedure at all six of its hospitals across New England.

For additional information, please contact Laurie Fullerton, Public Relations Director at Biocell Center, at laurie.fullerton@biocellcenter.com, 781-391-2040, or Chris Murphy, Director of Media Relations, Caritas Christi, 617-562-5652, christopher.murphy@caritaschristi.org.

This release was issued through eReleases(TM).  For more information, visit http://www.ereleases.com.  

SOURCE Biocell Center Corporation

Back to top
'/>"/>
SOURCE Biocell Center Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Scientists Spot Brains Free Will Center
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
5. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
6. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
7. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
8. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
9. Governor Rendell Proclaims Sept. 9-15 as Senior Community Center Week
10. Concentra Opens On-Site Medical Unit at World Trade Center Site
11. Workers Win Contract at St. Francis Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: